Open AccessThe efficacy and safety of combined ipilimumab and nivolumab versus ipilimumab in patients with Stage III/IV unresectable melanoma: A systematic review and meta-analysis
Author(s) -
Yuqing Zhu,
Hui Cheng,
Min-Hong Zhong,
Yijie Hu,
Qiushuang Li,
Xiangfu Gao,
Shan Liu
Publication year - 2021
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_1669_21
Subject(s) - medicine , ipilimumab , nivolumab , hazard ratio , confidence interval , meta analysis , cochrane library , adverse effect , randomized controlled trial , relative risk , combination therapy , oncology , gastroenterology , cancer , immunotherapy
In this meta-analysis, we compared the clinical efficacy and safety of ipilimumab/nivolumab combination therapy with those of ipilimumab monotherapy for stage III/IV unresectable melanoma.